^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Empliciti (elotuzumab)

    i
    Other names: BMS-901608, HuLuc63, PDL063, BMS901608, BMS 901608, HuLuc-63, PDL 036, PDL-063
    Company:
    AbbVie, BMS
    Drug class:
    CS-1 inhibitor
    Related drugs:
    Apply
    Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis (NCT04517851)
    Phase 2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    02/10/2025
    Initiation :
    02/10/2021
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    JAK2 • IL1R1 • SLAMF7
    |
    JAK2 V617F
    |
    Empliciti (elotuzumab)
    Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma (RV-MM-PI-0691) (NCT01729091)
    Phase 2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    04/18/2024
    Initiation :
    06/10/2013
    Primary completion :
    06/30/2025
    Completion :
    06/30/2025
    TP53
    |
    TP53 mutation
    |
    lenalidomide • melphalan • Empliciti (elotuzumab)
    A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma (NCT05028348)
    Phase 3
    European Myeloma Network
    Recruiting
    Last update posted :
    02/22/2023
    Initiation :
    04/19/2022
    Primary completion :
    03/01/2026
    Completion :
    03/01/2029
    CD4
    |
    Xpovio (selinexor) • dexamethasone • pomalidomide • Empliciti (elotuzumab)
    2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT) (NCT03003728)
    Phase 2
    University of Arkansas
    Withdrawn
    Last update posted :
    07/10/2020
    Initiation :
    11/01/2019
    Primary completion :
    07/08/2020
    Completion :
    07/08/2020
    CD34
    |
    melphalan • Empliciti (elotuzumab) • Anktiva (nogapendekin alfa inbakicept-pmln)
    Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma (NCT01441973)
    Phase 2
    Bristol-Myers Squibb
    Completed
    Last update posted :
    01/23/2018
    Initiation :
    12/28/2011
    Primary completion :
    05/30/2014
    Completion :
    01/17/2017
    NCAM1
    |
    Empliciti (elotuzumab)